pirtobrutinib,rituximab,venetoclax
eli lilly,roche,abbvie
['ritux', 'bruin', 'leusm', 'cll', 'rituximab', 'bruin cll-322', 'venetoclax', 'lymsm', 'loxo', 'valent ,(-prevalent)', 'valent ,(-prevalent),(-equivalent),(-bivalent)']
bruin cll-322: a phase 3 open-label, randomized study of fixed duration non-covalent (reversible) btki + venetoclax &amp; rituximab vs. venetoclax &amp; rituximab in previously treated cll/sll. #leusm #lymsm view the #asco23 trial in progress poster: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK